WO2014049566A2 - Nutritional kit - Google Patents
Nutritional kit Download PDFInfo
- Publication number
- WO2014049566A2 WO2014049566A2 PCT/IB2013/058945 IB2013058945W WO2014049566A2 WO 2014049566 A2 WO2014049566 A2 WO 2014049566A2 IB 2013058945 W IB2013058945 W IB 2013058945W WO 2014049566 A2 WO2014049566 A2 WO 2014049566A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- kit
- approximately
- nutritional composition
- nutritional
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims description 40
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 86
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 58
- 229910052742 iron Inorganic materials 0.000 claims abstract description 43
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 26
- 239000011707 mineral Substances 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 26
- 239000011782 vitamin Substances 0.000 claims abstract description 26
- 229930003231 vitamin Natural products 0.000 claims abstract description 24
- 235000013343 vitamin Nutrition 0.000 claims abstract description 24
- 102000006386 Myelin Proteins Human genes 0.000 claims abstract description 23
- 108010083674 Myelin Proteins Proteins 0.000 claims abstract description 23
- 210000005012 myelin Anatomy 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 235000020776 essential amino acid Nutrition 0.000 claims abstract description 10
- 239000003797 essential amino acid Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 9
- 230000006378 damage Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 37
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 34
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 32
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 28
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 27
- 229960002061 ergocalciferol Drugs 0.000 claims description 27
- 235000001892 vitamin D2 Nutrition 0.000 claims description 27
- 239000011653 vitamin D2 Substances 0.000 claims description 27
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 27
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 26
- 235000005282 vitamin D3 Nutrition 0.000 claims description 25
- 239000011647 vitamin D3 Substances 0.000 claims description 25
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 25
- 229940021056 vitamin d3 Drugs 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 21
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 21
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 21
- 229930003471 Vitamin B2 Natural products 0.000 claims description 21
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 21
- 239000011648 beta-carotene Substances 0.000 claims description 21
- 235000013734 beta-carotene Nutrition 0.000 claims description 21
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 21
- 229960002747 betacarotene Drugs 0.000 claims description 21
- 229910052791 calcium Inorganic materials 0.000 claims description 21
- 239000011575 calcium Substances 0.000 claims description 21
- 229960002477 riboflavin Drugs 0.000 claims description 21
- 235000019164 vitamin B2 Nutrition 0.000 claims description 21
- 239000011716 vitamin B2 Substances 0.000 claims description 21
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 21
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 20
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 20
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 20
- 229910052804 chromium Inorganic materials 0.000 claims description 20
- 239000011651 chromium Substances 0.000 claims description 20
- 229910052802 copper Inorganic materials 0.000 claims description 20
- 239000010949 copper Substances 0.000 claims description 20
- 239000011777 magnesium Substances 0.000 claims description 20
- 229910052749 magnesium Inorganic materials 0.000 claims description 20
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 19
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 19
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 19
- 229930003451 Vitamin B1 Natural products 0.000 claims description 19
- 229930003268 Vitamin C Natural products 0.000 claims description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000787 lecithin Substances 0.000 claims description 19
- 229940067606 lecithin Drugs 0.000 claims description 19
- 235000010445 lecithin Nutrition 0.000 claims description 19
- 150000002632 lipids Chemical class 0.000 claims description 19
- 229910052750 molybdenum Inorganic materials 0.000 claims description 19
- 239000011733 molybdenum Substances 0.000 claims description 19
- 229940119224 salmon oil Drugs 0.000 claims description 19
- 229960003495 thiamine Drugs 0.000 claims description 19
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 19
- 229960004799 tryptophan Drugs 0.000 claims description 19
- 235000010374 vitamin B1 Nutrition 0.000 claims description 19
- 239000011691 vitamin B1 Substances 0.000 claims description 19
- 235000019154 vitamin C Nutrition 0.000 claims description 19
- 239000011718 vitamin C Substances 0.000 claims description 19
- 239000011701 zinc Substances 0.000 claims description 19
- 229910052725 zinc Inorganic materials 0.000 claims description 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
- 239000004472 Lysine Substances 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 18
- 229930003779 Vitamin B12 Natural products 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 18
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 18
- 229960000310 isoleucine Drugs 0.000 claims description 18
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 18
- 229930182817 methionine Natural products 0.000 claims description 18
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 18
- 239000004474 valine Substances 0.000 claims description 18
- 235000019163 vitamin B12 Nutrition 0.000 claims description 18
- 239000011715 vitamin B12 Substances 0.000 claims description 18
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- 235000008524 evening primrose extract Nutrition 0.000 claims description 17
- 229940089020 evening primrose oil Drugs 0.000 claims description 17
- 239000010475 evening primrose oil Substances 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 239000011669 selenium Substances 0.000 claims description 17
- 229910052711 selenium Inorganic materials 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 16
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 16
- 235000019158 vitamin B6 Nutrition 0.000 claims description 16
- 239000011726 vitamin B6 Substances 0.000 claims description 16
- 229940011671 vitamin b6 Drugs 0.000 claims description 16
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 15
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 15
- 235000019152 folic acid Nutrition 0.000 claims description 14
- 239000011724 folic acid Substances 0.000 claims description 14
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 12
- 229960000304 folic acid Drugs 0.000 claims description 12
- 229940014662 pantothenate Drugs 0.000 claims description 12
- 235000019161 pantothenic acid Nutrition 0.000 claims description 12
- 239000011713 pantothenic acid Substances 0.000 claims description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 10
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000000378 dietary effect Effects 0.000 claims description 8
- 239000006186 oral dosage form Substances 0.000 claims description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- 239000006035 Tryptophane Substances 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 abstract description 20
- 235000001014 amino acid Nutrition 0.000 description 18
- 208000016192 Demyelinating disease Diseases 0.000 description 15
- 229960002885 histidine Drugs 0.000 description 13
- 229960003136 leucine Drugs 0.000 description 13
- 229960004452 methionine Drugs 0.000 description 13
- 229960005190 phenylalanine Drugs 0.000 description 13
- 229960004295 valine Drugs 0.000 description 13
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 12
- 229960002898 threonine Drugs 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- 239000013522 chelant Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- -1 glycinate amino acid Chemical class 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 235000015496 breakfast cereal Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002506 iron compounds Chemical class 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 235000007672 methylcobalamin Nutrition 0.000 description 2
- 239000011585 methylcobalamin Substances 0.000 description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 229960003189 potassium gluconate Drugs 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000020330 rooibos tea Nutrition 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 229960002718 selenomethionine Drugs 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 108700029294 Drosophila acanthoptera CYP12B1 Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229940037720 boron 3 mg Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940019216 evening primrose oil 500 mg Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229940019142 folic acid 5 mg Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229940037038 pantothenate 10 mg Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 229940036173 salmon oil 500 mg Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 229940023356 vitamin b6 10 mg Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
Definitions
- the present invention relates to a nutritional a kit for use in the treatment and management of demyelinating diseases.
- Demyelinating diseases such as Multiple Sclerosis ("MS"), clinically isolated syndrome, psychiatric diseases such as depression and bipolar disorder, ADHD, mild cognitive impairment, developmental delay and peripheral demyelinating disorders are difficult to accurately diagnose and treat. Patients suffering from demyelinating diseases present with various clinical symptoms, which is illustrated well by MS.
- MS Multiple Sclerosis
- MS is a disorder in which autoreactive immune responses are involved in the attack on myelinated axons, causing lesions or scars in the insulating myelin sheth protecting axons. These lesions then interfere with the conduction of signals to the periphery.
- the disease process is typically progressive and can lead to chronic disability.
- the central nervous system is made up of nerves that act as the body's messenger system. Each nerve is covered by a fatty substance called myelin, which insulates the nerves and helps in the transmission of nerve impulses between the brain and other parts of the body. With demyelinating diseases such as MS, the myelin that protects the nerves is destroyed, causing scar tissue. This process is called demyelination. Without the myelin, electrical signals transmitted throughout the brain and spinal cord are disrupted or halted. The brain thus becomes unable to send and receive messages, causing a multitude of symptoms.
- Myelin regeneration is a prerequisite for remission and various nutrients, such as iron, essential amino acids, lipids, vitamins and minerals play an important role in the regeneration of myelin.
- Suitable treatment of demyelinating diseases depends largely on the type of demyelinating disease that the patient suffers from and the symptoms that a patient presents with. In the case of acute attacks, patients must often be hospitalised. Furthermore, the routine therapy for acute relapses typically includes the administration of high doses of intravenous corticosteroids. Although corticosteroid treatments appear to be effective in short term relief, it appears to have little or no significant impact on long-term recovery.
- DMD Disease Modifying Drugs
- interferon such as interferon, glatiramer acetate, fingolimod and tysabri
- DMD's target inflammation and these drugs are designed to reduce the damage caused by relapses.
- a common problem associated with DMD's are that they target the immune system, causing unpleasant and sometimes harmful side-effects. Treating a patient with DMD's can be very expensive, making it unaffordable to many. The use of injections is often necessary, necessitating multiple visits to a doctor, clinic or hospital. According to a study conducted by Modi et al in 2008, only about 22% of South Africans diagnosed with MS are treated with DMD's.
- Nutritional supplement regimens may also be used in an attempt to reduce or even stop MS progression. These regimens typically include vitamins, minerals and more specialized nutritional elements. The problem associated with nutritional supplement regimens is that a wide variety of nutritional supplements are often needed in specific dosages by a patient suffering from MS or other demyelinating diseases. It can be very difficult to obtain each of the different nutritional supplements in the correct dosages from a store or pharmacy.
- the typical nutritional supplement regimen for treating MS comprises in excess of 20 different nutritional supplements.
- the intake of nutritional supplements plays a very important role in the treatment of demyelinating diseases, the intake of excessive amounts of a specific nutritional supplement may be to the detriment of patients.
- Excess consumption of iron, for instance, can cause various stomach problems such as nausea, constipation and abdominal pain, whilst side-effects such as discoloration of teeth and skin disorders have also been reported.
- a kit for use in a method of inhibiting damage or demise of myelin-producing cells comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the kit having a container with a plurality of distinct compartments, each compartment containing a plurality of dosage units of the nutritional supplements, the nutritional supplements constituting sufficient daily multi-unit doses for a period of time.
- the nutritional supplements to be selected from iron, essential amino acids, lipids, minerals and vitamins.
- the amino acids to be selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine;
- the lipids to be selected from the list comprising evening primrose oil, salmon oil and lecithin;
- the vitamins to be selected from the list comprising beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3;
- the minerals to be selected from the list comprising calcium, magnesium, copper, zinc, manganese, chromium, molybdenum and selenium.
- the nutritional supplements to be administered as an oral dosage forms such as tablets, capsules, fluids, powders or dietary shakes; and for a dosage form to include two or more of the nutritional supplements.
- kit to include one or more amino acids in the following amounts:
- kit to include one or more lipids in the following amounts: approximately 500mg evening primrose oil; approximately 500mg salmon oil; and approximately 300mg lecithin.
- kit to include one or more vitamins in the following amounts:
- kit to include one or more minerals in the following amounts:
- kit to include 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 ⁇ g vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100 ⁇ g chromium, 100 ⁇ g molybdenum and 60 ⁇ g selenium and optionally 15mg iron.
- each compartment of the kit to contain multiple dosage units of the same nutritional supplement; alternatively for the kit to have at least 28 compartments containing a daily dosage unit of each of the different nutritional supplements; for each of the compartments to have a separate cap and for the kit to have at least one lid covering the compartments and corresponding caps.
- a nutritional composition for use in a method of inhibiting damage or demise of myelin-producing cells, which method comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the nutritional supplements including essential amino acids, lipids, minerals, vitamins and optionally iron.
- the nutritional composition to include one or more amino acids selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine in the following amounts:
- the nutritional composition to include one or more lipids in the following amounts: about 500mg evening primrose oil;
- the nutritional composition to include one or more vitamins in the following amounts:
- the nutritional composition to include one or more minerals in the following amounts:
- the nutritional composition comprises 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 ⁇ g vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100 ⁇ g chromium, 100 ⁇ g molybdenum and 60 ⁇ g selenium and optionally 15mg iron.
- Still further features of this aspect of the invention provide for the nutritional supplements of the nutritional composition to be contained in a plurality of dosage units; for the dosage units to be selected from tablets, capsules, fluids, powders and dietary shakes; and for one or more of the dosage units to contain two or more of the nutritional supplements.
- a kit comprises a container having a plurality of distinct compartments. Each of the compartments contains a plurality of dosage units of various nutritional supplements.
- the plurality of nutritional supplements constitutes a multi-unit dose used in a method of inhibiting damage or demise of myelin-producing cells.
- each compartment contains multiple dosage units of the same nutritional supplement.
- the kit has at least 28 compartments containing a daily dosage unit of each of the different nutritional supplements. It is appreciated that the kit can also comprise 30 or 31 compartments, each compartment representing a day of the month. Each of the compartments may have a separate cap as it may not be necessary to consume each of the supplements every day. A single lid may also be provided to cover the separate compartments and corresponding caps.
- the caps may be of the screw-on type, but a person skilled in the art will appreciate that various different types of caps may be used.
- the compartments may also be arranged in a specific sequence such as days of the month or in a sequence indicating days of the week and weeks of the month.
- each of the compartments may depict certain information, or may include means for receiving substantially flat articles, such as stickers or slide-in plates depicting information such as dosages and side effects.
- the kit may also include one or more additional storage areas for storing articles such as documents pertaining to the nutritional supplements and medical reports. Additional storage areas may also be included in the kit to store spoons or measuring devices used for measuring fluids or powders.
- kit may be manufactured in different shapes and sizes and also that the size and depth of the compartments may vary in order to accommodate the various different nutritional supplements.
- the nutritional supplements are administered to patients in need of such treatment in therapeutically effective amounts. If a person suffers from demyelinating diseases, important myelin producing cells glial cells, such as oligodendrocytes and Schwann cells are often destroyed. In order for remyelination of lesions to occur, it is thus important to inhibit, ameliorate or alleviate the apoptosis of myelin-producing cells.
- Various nutritional supplements are needed in order to achieve this in order to improve myelin repair and regeneration.
- the nutritional supplements typically comprise iron, essential amino acids, lipids, minerals and vitamins. Each supplement plays a very specific and important role in the regeneration of myelin.
- Vascular damage in MS is implicated in the finding of higher homocysteine levels in patients diagnosed with MS.
- Prolonged iron deficiency anaemia is associated with gastritis and atrophy of lands producing intrinsic factor in the stomach. This leads to a decrease in vitamin B12 absorption by the body.
- Optimal functioning of the folate-vitamin B12-methyl transfer cycle continuously providing activated methyl-groups is a prerequisite for myelin production and maintenance and long-term deficiencies such as an iron deficiency may cause demyelination diseases of the brain and spinal cord.
- Iron will typically be administered as a bisglycinate amino acid chelate and may be provided as a separate dosage form and may be excluded from the kit depending on the iron levels of a patient.
- the kit may include one or more of the following amino acids: leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine.
- the kit typically contains one or more of the amino acids in the following amounts: approximately 1235mg leucine;
- the kit may further include one or more of evening primrose oil, lecithin and fish oils such as salmon oil, which are rich in essential omega oils.
- the kit typically includes one or more of these lipids in the following amounts:
- the kit also includes one or more of the following vitamins: beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3.
- the kit typically includes one or more of these vitamins in the following amounts: approximately 3mg beta carotene;
- panthothenate approximately 10mg panthothenate
- vitamin D2 in the kit is vital in some cases.
- a genetic defect occurs in the enzyme CYP12B1 , which activates vitamin D3.
- the administering of vitamin D2 will be beneficial at the activated forms of both vitamin D3 and vitamin D2 bind to vitamin D receptors and are therefore equally metabolically active.
- a genetic metabolic block often present in patients with demyelination diseases, is bypassed by stimulation an alternative metabolic pathway.
- genetic defects in the enzyme MTHFR which activates tetrahydrofolate, can reduce the activity of the enzyme by 30% or more, affecting myelin production and repair. Increasing the amount of folate included in the kit, the activity of the enzyme is restored.
- the kit may include the following minerals: calcium, magnesium, copper, zinc, manganese, chromium, molybdenum or selenium.
- the kit typically includes one or more of these minerals in the following amounts: approximately 28.5mg calcium;
- the nutritional kit may include 10% more or 10% less of iron, amino acids, lipids, vitamins and minerals as set out above.
- the kit will include 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 ⁇ g vitamin B12, 10mg vitamin B6, 10mg pantothenate, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 10C ⁇ g chromium, 100 ⁇ g molybdenum and 6C ⁇ g selenium and optionally 15mg iron, 50 000 IU vitamin D2 and 500 IU vitamin D3.
- the nutritional supplements may be oral dosage forms such as powders, dietary shakes, tablets, capsules or fluids.
- the nutritional supplements are included in the compartments as a first dosage unit containing iron; a second dosage unit in the form of protein powder containing one or more of rice protein, whey protein, soy protein and lecithin; a third dosage unit containing multiple vitamins; a fourth dosage unit containing antioxidants; a fifth dosage unit containing minerals and trace elements; a sixth dosage unit containing salmon oil; and a seventh dosage unit containing evening primrose oil.
- the first dosage unit may contain iron as bisglycinate amino acid chelate or other similar iron compounds providing between 10.50mg and 17.5mg, but preferably 14mg elemental iron per day for approximately one month.
- the iron may be provided in a separate container and added to the kit for patients who present with low iron parameters.
- the second dosage unit may consist of whey powder, soy powder or rice powder which provide between 20g and 40g, but preferably 30g of protein per day, in combination with between 300mg and 1200mg lecithin per day for approximately one month.
- the protein powder typically includes:
- the third dosage unit may be in an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg co- enzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of methylcobalamin; approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotenamid, 10mg of vitamin B2 and approximately 500 IU vitamin D3.
- an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg co- enzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of methylcobalamin; approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotenamid, 10mg of vitamin B2 and
- the concentration of vitamin D3 will typically be 500 IU per day, however if a genetic variation is discovered in a patient that blocks the activation of vitamin D3, vitamin D2 may be added to the regimen.
- the concentration of vitamin D2 will typically be 50 000 IU per day until blood levels normalise to 50ng - 100ng.
- the concentration of vitamin D2 advised may then be reduced to 50 000 IU 3 times per week.
- the fourth dosage unit may be in the form of a capsule or tablet containing approximately 120mg alpha lipoic acid, approximately 4mg of 5% extract of astaxanthin, approximately 30mg of grape seed extract, approximately 30mg of resveratrol, approximately 100mg of rooibos teas exteract, approximately 50 mg roship vitamin C, approximately 10mg 0.3% sulforaphane, approximately 1665 IU vitamin A in the form of beta carotene, approximately 15 IU alpha tocopherol and approximately 100 meg elemental L- selenomethionine.
- the fourth dosage unit is illustrated in table 3 below.
- the fifth dosage unit may be a capsule or tablet containing approximately 3mg boron, approximately 100mg calcium, approximately 120 meg chromium in the form of niccotinoglycinate amino acid chelate, approximately 2mg copper, approximately 100mg magnesium as glycinate amino acid chelate or magnesium oxide, approximately 75 meg molybdenum, approximately 100mg potassium in the form of potassium glycinate amino acid complex or potassium gluconate or asparate or citrate or iodide, approximately 15mg zinc in the form of ACC, approximately 100mg salmon oil and approximately 500mg evening primrose oil.
- the fifth dosage unit is illustrated in table 4 below.
- the sixth dosage unit typically contains 1000mg salmon oil and 500mg evening primrose oil as illustrated in table 5.
- additional Salmon Oil may be taken in the morning, the concentration whereof may vary between 500 - 1000 mg. This will be supplied as additional capsules.
- a seventh dosage unit such as a capsule containing Lecithin, may be added if it is not included in the protein shake, or in addition to that which is contained in the protein shake:
- the Lecithin may also be supplied as granules to be sprinkled over breakfast cereal.
- kits are used to treat patients with a regimen comprising of many different tablets, capsules, fluids or powders. It is difficult to find all the nutritional supplements needed from a single store or pharmacy. Even if all the supplements can be obtained from a single store or pharmacy, it can be a hassle to carry the different nutritional supplements around.
- An advantage of the kit is that all the nutritional supplements are contained in a single kit which is easy to carry and which may include instructions and important information as to the use thereof. This will increase patient compliance and consequently increase the therapeutic benefits of using nutritional supplements.
- EDSS Expanded Disability Status Scale
- Table 7 illustrates the results of the EDSS neurological examination of the 12 compliant patents at baseline and after 6 months.
- the mean total EDSS score improved significantly from 3.50 ⁇ 0.57 at baseline to 2.45 ⁇ 0.50 at endpoint. The most dramatic improvement was recorded in the cerebral sub- scale of the EDS, which measures mood and mentation. All patients recorded zero deficits after 6 months. Two patents had a score of 0 on the total EDSS after 6 months, indicating no neurological disability.
- Raphah Regimen including iron
- Vitamin D was measured in a person diagnosed with MS who was wheelchair bound. Her serum vitamin D concentration was 6 ng/l, whereas values less than 30 ng/l are considered to be deficient. Values of 60 - 100 ng/l are considered to be optimal. Due to the exceptionally low serum value of vitamin D it was decided to prescribe 50000 IU of vitamin D2, to bypass possible genetic blocks in vitamin D3 activation. The results were surprising. Within a day the patient experienced improvement in three areas and which are enduring as long as she takes the vitamin D2: in her balance, her eyesight and her mood.
- a nutritional composition for use in a method of inhibiting damage or demise of myelin-producing cells, the method comprising administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the composition including iron, essential amino acids, lipids, minerals and vitamins.
- the composition including iron, essential amino acids, lipids, minerals and vitamins.
- the nutritional supplements are typically contained in a plurality of dosage units, together making up the nutritional composition.
- the dosage units include tablets, capsules, fluids, powders and dietary shakes.
- the nutritional composition may include one of more amino acids in the following amounts:
- the nutritional composition may further include one or more of the following lipids, typically in the following amounts: Approximately 500mg evening primrose oil; approximately 500mg salmon oil; and approximately 300mg lecithin.
- the nutritional composition may include one or more of the following vitamins, typically in the following amounts:
- panthothenate approximately 10mg panthothenate
- the nutritional composition may include the following minerals, typically in the following amounts:
- the nutritional composition may include 10% more or 10% less of each of the iron, amino acids, lipids, vitamins and minerals as set out above.
- the nutritional composition comprises multiple dosage units, such as tablets, capsules, powders, dietary shakes and fluids.
- the multiple dosage units collectively contain 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 ⁇ g vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100 ⁇ g chromium, 100 ⁇ g molybden
- one or more of the dosage units may include multiple nutritional supplements and that the nutritional supplements may be oral dosage forms such as powders, dietary shakes, tablets, capsules or fluids.
- the nutritional composition comprises its nutritional supplements in the following dosage units:
- a first dosage unit such as a tablet, capsule or other suitable dosage form containing iron
- a second dosage unit such as protein powder containing one or more of rice protein, whey protein, soy protein and lecithin
- a third dosage unit containing multiple vitamins
- a fourth dosage unit containing antioxidants
- a fifth dosage unit containing minerals and trace elements
- a sixth dosage unit containing salmon oil
- a seventh dosage unit containing evening primrose oil.
- the first dosage unit may contain iron as bisglycinate amino acid chelate or other similar iron compounds providing between 10.50mg and 17.5mg, but preferably 14mg elemental iron per day for approximately one month.
- the second dosage unit may be a protein powder consisting of whey powder, soy powder or rice powder which provide between 20g and 40g, but preferably 30g of protein per day, in combination with between 300mg and 1200mg lecithin per day for approximately one month.
- the protein powder typically includes: g in
- the third dosage unit may be in an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg coenzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of methylcobalamin;approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotenamid, 10mg of vitamin B2 and approximately 500 IU vitamin D3.
- an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg coenzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of methylcobalamin;approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotena
- the typical formulation of the third dosage unit is illustrated in table 1 1 .
- the concentration of vitamin D3 will typically be 500 IU per day, however if a genetic variation is discovered in a patient that blocks the activation of vitamin D3, vitamin D2 may be added to the regimen.
- the concentration of vitamin D2 will typically be 50 000 IU per day until blood levels normalise to 50ng - 100ng.
- the concentration of vitamin D2 advised may then be reduced to 50 000 IU 3 times per week.
- the fourth dosage unit may be in the form of a capsule or tablet containing approximately 120mg alpha lipoic acid, approximately 4mg of 5% extract of astaxanthin, approximately 30mg of grape seed extract, approximately 30mg of resveratrol, approximately 100mg of rooibos teas exteract, approximately 50 mg roship vitamin C, approximately 10mg 0.3% sulforaphane, approximately 1665 IU vitamin A in the form of beta carotene, approximately 15 IU alpha tocopherol and approximately 100 meg elemental L- selenomethionine.
- the fourth dosage unit is illustrated in table 12 below.
- the fifth dosage unit may be a capsule or tablet containing approximately 3mg boron, approximately 100mg calcium, approximately 120 meg chromium in the form of niccotinoglycinate amino acid chelate, approximately 2mg copper, approximately 100mg magnesium as glycinate amino acid chelate or magnesium oxide, approximately 75 meg molybdenum, approximately 100mg potassium in the form of potassium glycinate amino acid complex or potassium gluconate or asparate or citrate or iodide, approximately 15mg zinc in the form of ACC, approximately 100mg salmon oil and approximately 500mg evening primrose oil.
- the fifth dosage unit is illustrated in table 13 below.
- the sixth dosage unit typically contains 1000mg salmon oil and 500mg evening primrose oil as illustrated in table 14.
- DHA Docosahexaenoic
- additional Salmon Oil may be taken in the morning, the concentration whereof may vary between 500 - 1000 mg. This will be supplied as additional capsules.
- a seventh dosage unit consisting of capsules containing Lecithin, may be added if it is not included in the protein shake, or in addition to that which is contained in the protein shake:
- the Lecithin may also be supplied as granules to be sprinkled over breakfast cereal.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kit for use in a method of inhibiting damage or demise of myelin-producing cells is disclosed. The method includes administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements. The kit has a container with a plurality of distinct compartments, each compartment containing a plurality of dosage units of the nutritional supplements, such as minerals, vitamins, essential amino acids and iron. The nutritional supplements constitutes sufficient daily multi-unit doses for a period of time.
Description
NUTRITIONAL KIT
FIELD OF THE INVENTION
The present invention relates to a nutritional a kit for use in the treatment and management of demyelinating diseases.
BACKGROUND TO THE INVENTION
Demyelinating diseases such as Multiple Sclerosis ("MS"), clinically isolated syndrome, psychiatric diseases such as depression and bipolar disorder, ADHD, mild cognitive impairment, developmental delay and peripheral demyelinating disorders are difficult to accurately diagnose and treat. Patients suffering from demyelinating diseases present with various clinical symptoms, which is illustrated well by MS.
MS is a disorder in which autoreactive immune responses are involved in the attack on myelinated axons, causing lesions or scars in the insulating myelin sheth protecting axons. These lesions then interfere with the conduction of signals to the periphery. The disease process is typically progressive and can lead to chronic disability.
Patients sometimes experience a remission after initial diagnosis. After an initial remission, some patients experience few symptoms for long periods of time, while others deteriorate rapidly.
The central nervous system is made up of nerves that act as the body's messenger system. Each nerve is covered by a fatty substance called myelin, which insulates the nerves and helps in the transmission of nerve impulses between the brain and other parts of the body. With demyelinating diseases such as MS, the myelin that protects the nerves is destroyed, causing scar tissue. This process is called demyelination. Without the myelin,
electrical signals transmitted throughout the brain and spinal cord are disrupted or halted. The brain thus becomes unable to send and receive messages, causing a multitude of symptoms.
Myelin regeneration is a prerequisite for remission and various nutrients, such as iron, essential amino acids, lipids, vitamins and minerals play an important role in the regeneration of myelin.
Suitable treatment of demyelinating diseases depends largely on the type of demyelinating disease that the patient suffers from and the symptoms that a patient presents with. In the case of acute attacks, patients must often be hospitalised. Furthermore, the routine therapy for acute relapses typically includes the administration of high doses of intravenous corticosteroids. Although corticosteroid treatments appear to be effective in short term relief, it appears to have little or no significant impact on long-term recovery.
Disease Modifying Drugs ("DMD") such as interferon, glatiramer acetate, fingolimod and tysabri are often used to delay long term progression of MS and to reduce the number of new lesions forming. DMD's target inflammation and these drugs are designed to reduce the damage caused by relapses. A common problem associated with DMD's are that they target the immune system, causing unpleasant and sometimes harmful side-effects. Treating a patient with DMD's can be very expensive, making it unaffordable to many. The use of injections is often necessary, necessitating multiple visits to a doctor, clinic or hospital. According to a study conducted by Modi et al in 2008, only about 22% of South Africans diagnosed with MS are treated with DMD's.
Nutritional supplement regimens may also be used in an attempt to reduce or even stop MS progression. These regimens typically include vitamins, minerals and more specialized nutritional elements. The problem associated with nutritional supplement regimens is that a wide variety of nutritional
supplements are often needed in specific dosages by a patient suffering from MS or other demyelinating diseases. It can be very difficult to obtain each of the different nutritional supplements in the correct dosages from a store or pharmacy.
Another problem is the wide variety of products containing nutritional supplements that are available. The typical nutritional supplement regimen for treating MS comprises in excess of 20 different nutritional supplements. Although the intake of nutritional supplements plays a very important role in the treatment of demyelinating diseases, the intake of excessive amounts of a specific nutritional supplement may be to the detriment of patients. Excess consumption of iron, for instance, can cause various stomach problems such as nausea, constipation and abdominal pain, whilst side-effects such as discoloration of teeth and skin disorders have also been reported.
It is thus very important for a patient to consume the correct dosages of nutritional supplements when treating demyelinating diseases, such as MS.
SUMMARY OF THE INVENTION
In accordance with a first aspect of this invention there is provided a kit for use in a method of inhibiting damage or demise of myelin-producing cells, which method comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the kit having a container with a plurality of distinct compartments, each compartment containing a plurality of dosage units of the nutritional supplements, the nutritional supplements constituting sufficient daily multi-unit doses for a period of time.
Further features of the invention provide for the nutritional supplements to be selected from iron, essential amino acids, lipids, minerals and vitamins.
Even further features provide for the amino acids to be selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine; for the lipids to be selected from the list comprising evening primrose oil, salmon oil and lecithin; for the vitamins to be selected from the list comprising beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3; and for the minerals to be selected from the list comprising calcium, magnesium, copper, zinc, manganese, chromium, molybdenum and selenium.
Yet further features provide for the nutritional supplements to be administered as an oral dosage forms such as tablets, capsules, fluids, powders or dietary shakes; and for a dosage form to include two or more of the nutritional supplements.
Even further features provide for the kit to include one or more amino acids in the following amounts:
1235mg leucine;
890mg isoleucine;
995mg lysine;
175mg tryptophane;
315mg methionine;
610mg phenylalanine;
570mg threonine;
840mg valine; and
340mg histidine.
Still further features provide for the kit to include one or more lipids in the following amounts: approximately 500mg evening primrose oil; approximately 500mg salmon oil; and approximately 300mg lecithin.
Yet further features provide for the kit to include one or more vitamins in the
following amounts:
3mg beta carotene;
350mg vitamin C;
40mg vitamin E;
3mg vitamin B1 ;
4mg vitamin B2;
20mg nicotinaminde;
24μg vitamin B12;
10mg vitamin B6;
10mg panthothenate;
50 000 IU vitamin D2; and
500 IU vitamin D3;
Even further features provide for the kit to include one or more minerals in the following amounts:
28.5mg calcium;
150mg magnesium;
1 mg copper;
15mg zinc;
2.5mg manganese;
100μg chromium;
100μg molybdenum; and
60μg selenium.
Yet further features provide for the kit to include 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100μg chromium, 100μg molybdenum and 60μg selenium and optionally
15mg iron.
Still further features provide for each compartment of the kit to contain multiple dosage units of the same nutritional supplement; alternatively for the kit to have at least 28 compartments containing a daily dosage unit of each of the different nutritional supplements; for each of the compartments to have a separate cap and for the kit to have at least one lid covering the compartments and corresponding caps.
In accordance with a second aspect of the invention, there is provided a nutritional composition for use in a method of inhibiting damage or demise of myelin-producing cells, which method comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the nutritional supplements including essential amino acids, lipids, minerals, vitamins and optionally iron.
Further features of this aspect of the invention provide for the nutritional composition to include one or more amino acids selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine in the following amounts:
1235mg leucine;
890mg isoleucine;
995mg lysine;
175mg tryptophane;
315mg methionine;
610mg phenylalanine;
570mg threonine;
840mg valine; and
340mg histidine.
Still further features of the invention provide for the nutritional composition to
include one or more lipids in the following amounts: about 500mg evening primrose oil;
about 500mg salmon oil;
about 300mg lecithin.
Even further features of the invention provide for the nutritional composition to include one or more vitamins in the following amounts:
3mg beta carotene;
350mg vitamin C;
40mg vitamin E;
3mg vitamin B1 ;
4mg vitamin B2;
20mg nicotinamide;
24μg vitamin B12;
10mg vitamin B6;
10mg panthothenate;
50 000 IU vitamin D2; and
500 IU vitamin D3;
Yet further features provide for the nutritional composition to include one or more minerals in the following amounts:
28.5mg calcium;
150mg magnesium;
1 mg copper;
15mg zinc;
2.5mg manganese;
100μg chromium;
100μg molybdenum; and
60μg selenium.
An even further feature of the invention provides for the nutritional composition to comprise 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100μg chromium, 100μg molybdenum and 60μg selenium and optionally 15mg iron.
Still further features of this aspect of the invention provide for the nutritional supplements of the nutritional composition to be contained in a plurality of dosage units; for the dosage units to be selected from tablets, capsules, fluids, powders and dietary shakes; and for one or more of the dosage units to contain two or more of the nutritional supplements.
DETAILED DESCRIPTION OF THE INVENTION
A kit is provided that comprises a container having a plurality of distinct compartments. Each of the compartments contains a plurality of dosage units of various nutritional supplements. The plurality of nutritional supplements constitutes a multi-unit dose used in a method of inhibiting damage or demise of myelin-producing cells.
In one embodiment of the invention, each compartment contains multiple dosage units of the same nutritional supplement.
In a different embodiment of the invention the kit has at least 28 compartments containing a daily dosage unit of each of the different nutritional supplements. It is appreciated that the kit can also comprise 30 or 31 compartments, each compartment representing a day of the month.
Each of the compartments may have a separate cap as it may not be necessary to consume each of the supplements every day. A single lid may also be provided to cover the separate compartments and corresponding caps.
The caps may be of the screw-on type, but a person skilled in the art will appreciate that various different types of caps may be used. The compartments may also be arranged in a specific sequence such as days of the month or in a sequence indicating days of the week and weeks of the month.
In a further embodiment each of the compartments may depict certain information, or may include means for receiving substantially flat articles, such as stickers or slide-in plates depicting information such as dosages and side effects.
The kit may also include one or more additional storage areas for storing articles such as documents pertaining to the nutritional supplements and medical reports. Additional storage areas may also be included in the kit to store spoons or measuring devices used for measuring fluids or powders.
It will be appreciated that the kit may be manufactured in different shapes and sizes and also that the size and depth of the compartments may vary in order to accommodate the various different nutritional supplements.
The nutritional supplements are administered to patients in need of such treatment in therapeutically effective amounts. If a person suffers from demyelinating diseases, important myelin producing cells glial cells, such as oligodendrocytes and Schwann cells are often destroyed. In order for remyelination of lesions to occur, it is thus important to inhibit, ameliorate or alleviate the apoptosis of myelin-producing cells.
Various nutritional supplements are needed in order to achieve this in order to improve myelin repair and regeneration. The nutritional supplements typically comprise iron, essential amino acids, lipids, minerals and vitamins. Each supplement plays a very specific and important role in the regeneration of myelin.
Some patients suffering from MS present with low blood iron concentrations. A prerequisite for the regeneration of myelin is sufficient levels of iron and a functional folate-vitamin B12-methylation pathway. Iron deficiency can result in a reduced amount of myelin in the spinal cord and white matter of patients. Studies further suggest that many of the enzymes involved in the biosynthetic pathways that produce myelin utilise iron as part of their catalytic centre.
Vascular damage in MS is implicated in the finding of higher homocysteine levels in patients diagnosed with MS. Prolonged iron deficiency anaemia is associated with gastritis and atrophy of lands producing intrinsic factor in the stomach. This leads to a decrease in vitamin B12 absorption by the body. Optimal functioning of the folate-vitamin B12-methyl transfer cycle continuously providing activated methyl-groups is a prerequisite for myelin production and maintenance and long-term deficiencies such as an iron deficiency may cause demyelination diseases of the brain and spinal cord.
Iron will typically be administered as a bisglycinate amino acid chelate and may be provided as a separate dosage form and may be excluded from the kit depending on the iron levels of a patient.
Essential amino acids are essential building blocks and play an important role in the general well-being of patients diagnosed with demyelinating diseases such as MS. A lack of these amino acids may disrupt metabolic processes causing and worsening symptoms such as weakness, fatigue and lethargy. The kit may include one or more of the following amino acids:
leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine. The kit typically contains one or more of the amino acids in the following amounts: approximately 1235mg leucine;
approximately 890mg isoleucine;
approximately 995mg lysine;
approximately 175mg tryptophane;
approximately 315mg methionine;
approximately 610mg phenylalanine;
approximately 570mg threonine;
approximately 840mg valine; and
approximately 340mg histidine.
The kit may further include one or more of evening primrose oil, lecithin and fish oils such as salmon oil, which are rich in essential omega oils. The kit typically includes one or more of these lipids in the following amounts:
Approximately 500mg evening primrose oil; approximately 500mg salmon oil; and approximately 300mg lecithin.
The kit also includes one or more of the following vitamins: beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3. The kit typically includes one or more of these vitamins in the following amounts: approximately 3mg beta carotene;
approximately 350mg vitamin C;
approximately 40mg vitamin E;
approximately 3mg vitamin B1 ;
approximately 4mg vitamin B2;
approximately 20mg nicotinaminde;
approximately 24μg vitamin B12;
approximately 10mg vitamin B6;
approximately 10mg panthothenate;
approximately 50 000 IU vitamin D2; and
approximately 500 IU vitamin D3.
The inclusion of vitamin D2 in the kit is vital in some cases. In some patients, a genetic defect occurs in the enzyme CYP12B1 , which activates vitamin D3. In such cases, the administering of vitamin D2 will be beneficial at the activated forms of both vitamin D3 and vitamin D2 bind to vitamin D receptors and are therefore equally metabolically active. In this manner, a genetic metabolic block often present in patients with demyelination diseases, is bypassed by stimulation an alternative metabolic pathway.
Similarly, genetic defects in the enzyme MTHFR, which activates tetrahydrofolate, can reduce the activity of the enzyme by 30% or more, affecting myelin production and repair. Increasing the amount of folate included in the kit, the activity of the enzyme is restored.
The kit may include the following minerals: calcium, magnesium, copper, zinc, manganese, chromium, molybdenum or selenium. The kit typically includes one or more of these minerals in the following amounts: approximately 28.5mg calcium;
approximately 150mg magnesium;
approximately 1 mg copper;
approximately 15mg zinc;
approximately 2.5mg manganese;
approximately 100μg chromium;
approximately 100μg molybdenum; and
approximately 60μg selenium.
It will be appreciated that the nutritional kit may include 10% more or 10%
less of iron, amino acids, lipids, vitamins and minerals as set out above.
In a preferred embodiment of the invention the kit will include 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 10C^g chromium, 100μg molybdenum and 6C^g selenium and optionally 15mg iron, 50 000 IU vitamin D2 and 500 IU vitamin D3.
The nutritional supplements may be oral dosage forms such as powders, dietary shakes, tablets, capsules or fluids.
In one embodiment of the invention the nutritional supplements are included in the compartments as a first dosage unit containing iron; a second dosage unit in the form of protein powder containing one or more of rice protein, whey protein, soy protein and lecithin; a third dosage unit containing multiple vitamins; a fourth dosage unit containing antioxidants; a fifth dosage unit containing minerals and trace elements; a sixth dosage unit containing salmon oil; and a seventh dosage unit containing evening primrose oil.
The first dosage unit may contain iron as bisglycinate amino acid chelate or other similar iron compounds providing between 10.50mg and 17.5mg, but preferably 14mg elemental iron per day for approximately one month. The iron may be provided in a separate container and added to the kit for patients who present with low iron parameters.
The second dosage unit may consist of whey powder, soy powder or rice powder which provide between 20g and 40g, but preferably 30g of protein per day, in combination with between 300mg and 1200mg lecithin per day for
approximately one month.
The protein powder typically includes:
Table 1
The third dosage unit may be in an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg co-
enzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of methylcobalamin; approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotenamid, 10mg of vitamin B2 and approximately 500 IU vitamin D3.
The typical formulation of the third dosage unit is illustrated in table 2.
Table 2
The concentration of vitamin D3 will typically be 500 IU per day, however if a genetic variation is discovered in a patient that blocks the activation of vitamin D3, vitamin D2 may be added to the regimen. The concentration of vitamin D2 will typically be 50 000 IU per day until blood levels normalise to 50ng - 100ng. The concentration of vitamin D2 advised may then be reduced to 50 000 IU 3 times per week.
The fourth dosage unit may be in the form of a capsule or tablet containing approximately 120mg alpha lipoic acid, approximately 4mg of 5% extract of astaxanthin, approximately 30mg of grape seed extract, approximately 30mg of resveratrol, approximately 100mg of rooibos teas exteract, approximately 50 mg roship vitamin C, approximately 10mg 0.3% sulforaphane,
approximately 1665 IU vitamin A in the form of beta carotene, approximately 15 IU alpha tocopherol and approximately 100 meg elemental L- selenomethionine.
The fourth dosage unit is illustrated in table 3 below.
Table 3
The fifth dosage unit may be a capsule or tablet containing approximately 3mg boron, approximately 100mg calcium, approximately 120 meg chromium in the form of niccotinoglycinate amino acid chelate, approximately 2mg copper, approximately 100mg magnesium as glycinate amino acid chelate or magnesium oxide, approximately 75 meg molybdenum, approximately 100mg potassium in the form of potassium glycinate amino acid complex or potassium gluconate or asparate or citrate or iodide, approximately 15mg zinc in the form of ACC, approximately 100mg salmon oil and approximately 500mg evening primrose oil. The fifth dosage unit is illustrated in table 4 below.
Minerals and Trace elements (Capsule
or Tablet) Values Units Lowest Highest
Table 4
The sixth dosage unit typically contains 1000mg salmon oil and 500mg evening primrose oil as illustrated in table 5.
Table 5
In the case where patients are diagnosed with a mental condition such as depression, additional Salmon Oil may be taken in the morning, the concentration whereof may vary between 500 - 1000 mg. This will be supplied as additional capsules.
A seventh dosage unit, such as a capsule containing Lecithin, may be added if it is not included in the protein shake, or in addition to that which is contained in the protein shake:
The Lecithin may also be supplied as granules to be sprinkled over breakfast
cereal.
Patient compliance is a problem when treating patients with a regimen comprising of many different tablets, capsules, fluids or powders. It is difficult to find all the nutritional supplements needed from a single store or pharmacy. Even if all the supplements can be obtained from a single store or pharmacy, it can be a hassle to carry the different nutritional supplements around. An advantage of the kit is that all the nutritional supplements are contained in a single kit which is easy to carry and which may include instructions and important information as to the use thereof. This will increase patient compliance and consequently increase the therapeutic benefits of using nutritional supplements.
Case Studies
Case Study 1
Thirty one patients suffering from MS took part in a case study directed at treatment with the nutritional supplements forming part of the nutritional kit of this invention.
As part of the study, an evaluation was made of the possible benefits of the nutritional supplement regimen of this invention. The "Raphah Regimen" as illustrated in table 6, was offered to each of the participants. Out of a smaller group of eighteen, twelve of the patients participating in the trial closely followed the regimen ("the compliant group"), while six of the patients did not follow the regimen ("the non-compliant group").
Expanded Disability Status Scale ("EDSS") neurological determinations and laboratory tests were conducted on the eighteen volunteers at baseline and after 6 months.
Vitamins and
RDA
Minerals
Iron* 15 mg/day Beta Carotene 3 mg -
Vitamin C 350mg
777
Essential amino acids Vitamin E 40mg
266
(e.a. diet milk shake)
Vitamin B1 3mg
200
Leucine 1235mg Vitamin B2 4mg 222
Isoleucine 890mg Nicotinamide 20mg
100
Lysine 995mg Folic Acid 5mg
1250
Tryptophan 175mg Vitamin B12** 24μ9
800
Methionine 315mg Vitamin B6 10mg
500
Phenylalanine 610mg Pantothenate 10mg 130
Treonine 570mg Calcium 28.5mg 2
Valine 840mg Magnesium 150mg
37
Histidine 340mg Copper 1mg 50
Zinc 15mg 100
Lipids Manaanese 2.5m -
Evening Primrose Oil 500mg Chromium 100μ9 -
Salmon Oil 500mg Molybdenum 100μ9 -
Lecithin 300mg Selenium 60μ9-
Table 6
Table 7 illustrates the results of the EDSS neurological examination of the 12 compliant patents at baseline and after 6 months. The mean total EDSS score improved significantly from 3.50±0.57 at baseline to 2.45±0.50 at endpoint. The most dramatic improvement was recorded in the cerebral sub- scale of the EDS, which measures mood and mentation. All patients recorded zero deficits after 6 months. Two patents had a score of 0 on the total EDSS after 6 months, indicating no neurological disability. For one of the compliant patients on the Raphah Regimen (including iron), MRI scans done after 6 months, after 24 months and again after 30 months, showed no additional intense lesions, and no disease activity on gadolinium enhancement.
Patients taking iron Patients not taking iron
Baseline 6 months Baseline 6 months
Serum iron 14.04±0.95 15.46±1 .82 19.23±1 .43 15.7512.21 (μπιοΙ/L)
Transferrin 2.48±0.13 2.14±0.1 1 2.29±0.15 2.0010.24
(g/L)
% sat 23.52±2.80 28.93±4.60 32.67±1 .29 30.1611 .92 Transferrin
Ferritin 30.55±4.61 34.26±6.41 108.55141 .19 1 12.02137.51 (ng/ml)
Haemoglobin 13.7±0.2 13.9±0.3 15.210.3 14.910.4 (g/dl)
Serum folate 25.6±6.8 31 .6±6.0 28.619.6 35.119.9 (nmol/L)
Homocysteine 9.1 ±2.1 6.4±0.4 6.711 .4 6.210.9
(μπιοΙ/L)
CRP 5.4±3.6 2.5±1 .2 1 .910.7 2.011 .0
Table 7
No-one from the compliant group was admitted to hospital for intravenous prednisone treatment during the 6 month period, while 1 on the non- compliant group received intravenous prednisone. The neurological outcome in the non-compliance group was deterioration from a mean total EDSS score of 4.8310.84 to 5.5010.55 at 6 months. There was also a significant difference in neurological outcome when the compliant and non-compliant groups were compared.
A follow-up analysis was conducted in respect of the patients several years later. Ten out of twelve patients from the compliant group showed a positive change in their EDSS scores. The change in EDSS scores ranged from 0.5 to 5.0. The EDSS score of one of the patients changed from 6 to 1 , which
marks a surprisingly significant change. On average the change in EDSS scores was positive 1 .3.
Conversely, none of the patients in the non-compliant group showed a positive change in their EDSS scores and the average EDSS score was negative 1 .7.
Case Study 2
A 3-year old boy was presented to Tygerberg Children's Hospital. At the time he suffered from sleepiness and poor coordination. The MRI brain scan showed inflammation of the white matter. He responded well to the cortisone that was given to suppress the inflammation and he seemed to make a full recovery. Four months later, however, he again presented with headache and drowsiness. This time the MRI showed widespread inflammation of different parts of his brain. Once again, he responded to cortisone and it was continued for 3 months. In spite of this, he again developed headaches and loss of vision several months later. At this stage his eyes and optic nerves were inflamed and high doses of cortisone had to be given to prevent him from losing his sight altogether. The rapid succession of these episodes identified the disease as MS.
At this point blood iron levels were determined, confirming extremely low iron levels. Daily supplementation began to build up the depleted body stores. Since reversing the iron deficiency, he has been completely free of further episodes of inflammation for more than 5 years.
Case Study 3
Iron studies done over a period of 5 years for a person taking the Rapha Regimen. The results are presented in table 8.
RANGE
Haemoglobin 12.0
(g/dl) 15.0 10.3 - Low 14 1 1 .7 12.9
Serum Iron 10.0
(μπτιοΙ/Ι) 30.0 3.9 - Low 4.3- Low 16.3 20.5
Transferrin (g/l) 2.0 - 3.6 4.5 - High 4.0 - High 3.7 3.6
4%- V 4%- V
Tf Saturation (%) 15 - 30 Low Low 17% 22%
7 - Very
Table 8
The normalisation of iron concentrations in the blood correlated with clinical outcome. The person's EDSS normalised to a score of 0 (no neurological deficit), and her MRI scans showed an improvement as well:
Neurologist's report: "FLAIR and T2 sequence hyperintensities which are perpendicularly orientated in relation to the ventricle (Dawson's fingers), and a pontine lesion" Follow-up MRI:
Radiologist's report: "The previous pontine lesion has resolved without residual signal changes and there is only slight scarring at the site of the previous right periventricular demyelinating lesions. No new or progressive lesions"
Case Study 4
Vitamin D was measured in a person diagnosed with MS who was wheelchair bound. Her serum vitamin D concentration was 6 ng/l, whereas values less than 30 ng/l are considered to be deficient. Values of 60 - 100 ng/l are considered to be optimal.
Due to the exceptionally low serum value of vitamin D it was decided to prescribe 50000 IU of vitamin D2, to bypass possible genetic blocks in vitamin D3 activation. The results were surprising. Within a day the patient experienced improvement in three areas and which are enduring as long as she takes the vitamin D2: in her balance, her eyesight and her mood.
Case Study 5
A female diagnosed with MS presented with very low iron parameters. She was wheelchair bound. After taking iron supplements for a year, her iron had improved to almost normal. She has been able to regain the use of her legs, and is not in the wheelchair any more. Follow-up studies are planned.
Table 9
Also provided, is a nutritional composition for use in a method of inhibiting damage or demise of myelin-producing cells, the method comprising
administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the composition including iron, essential amino acids, lipids, minerals and vitamins. In order for remyelination of lesions to occur, it is important to inhibit, ameliorate or alleviate the apoptosis of myelin-producing cells and each of the supplementary supplements plays a very specific and important role in the regeneration of myelin.
The nutritional supplements are typically contained in a plurality of dosage units, together making up the nutritional composition. The dosage units include tablets, capsules, fluids, powders and dietary shakes.
The nutritional composition may include one of more amino acids in the following amounts:
approximately 1235mg leucine;
approximately 890mg isoleucine;
approximately 995mg lysine;
approximately 175mg tryptophane;
approximately 315mg methionine;
approximately 610mg phenylalanine;
approximately 570mg threonine;
approximately 840mg valine; and
approximately 340mg histidine.
The nutritional composition may further include one or more of the following lipids, typically in the following amounts: Approximately 500mg evening primrose oil; approximately 500mg salmon oil; and approximately 300mg lecithin.
The nutritional composition may include one or more of the following vitamins, typically in the following amounts:
approximately 3mg beta carotene;
approximately 350mg vitamin C;
approximately 40mg vitamin E;
approximately 3mg vitamin B1 ;
approximately 4mg vitamin B2;
approximately 20mg nicotinamide;
approximately 24μg vitamin B12;
approximately 10mg vitamin B6;
approximately 10mg panthothenate;
approximately 50 000 IU vitamin D2; and
approximately 500 IU vitamin D3.
The nutritional composition may include the following minerals, typically in the following amounts:
approximately 28.5mg calcium;
approximately 150mg magnesium;
approximately 1 mg copper;
approximately 15mg zinc;
approximately 2.5mg manganese;
approximately 100μg chromium;
approximately 100μg molybdenum; and
approximately 60μg selenium.
It will be appreciated that the amounts mentioned in this specification are exemplary and that it should not be interpreted to be limiting. It is envisaged that the nutritional composition may include 10% more or 10% less of each of the iron, amino acids, lipids, vitamins and minerals as set out above.
In a preferred embodiment of the nutritional composition, it comprises multiple dosage units, such as tablets, capsules, powders, dietary shakes and fluids. The multiple dosage units collectively contain 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg
vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100μg chromium, 100μg molybdenum and 60μg selenium and optionally 15mg iron.
It should be appreciated that one or more of the dosage units may include multiple nutritional supplements and that the nutritional supplements may be oral dosage forms such as powders, dietary shakes, tablets, capsules or fluids.
In one embodiment, the nutritional composition comprises its nutritional supplements in the following dosage units:
A first dosage unit, such as a tablet, capsule or other suitable dosage form containing iron; a second dosage unit, such as protein powder containing one or more of rice protein, whey protein, soy protein and lecithin; a third dosage unit containing multiple vitamins; a fourth dosage unit containing antioxidants; a fifth dosage unit containing minerals and trace elements; a sixth dosage unit containing salmon oil; and a seventh dosage unit containing evening primrose oil.
The first dosage unit may contain iron as bisglycinate amino acid chelate or other similar iron compounds providing between 10.50mg and 17.5mg, but preferably 14mg elemental iron per day for approximately one month.
The second dosage unit may be a protein powder consisting of whey powder, soy powder or rice powder which provide between 20g and 40g, but preferably 30g of protein per day, in combination with between 300mg and 1200mg lecithin per day for approximately one month.
The protein powder typically includes:
g in
A
1000g Lowest Highest
L-Alanine 16.5 12.38 20.63
L-Arginine 21 .8 16.35 27.25
L-Aspartic Acid 35.3 26.48 44.13
L-Cysteine 2.4 1 .80 3.00
L-Glutamine 120.1 90.08 150.13
L-Glycine 10.6 7.95 13.25
L-Histidine 17.7 13.28 22.13
L-lsoleucine 28.3 21 .23 35.38
L-Leucine 47.7 35.78 59.63
L- Lysine 42.4 31 .80 53.00
L-Methionine 18.3 13.73 22.88
L-Phenylalanine 28.3 21 .23 35.38
L-Proline 5.9 4.43 7.38
L-Serine 33 24.75 41.25
L-Threonine 24.1 18.08 30.13
L-Tryptophan 3.5 2.63 4.38
L-Tyrosine 32.4 24.30 40.50
L-Valine 35.3 26.48 44.13
B
Calcium casseinate 240 180.00 300.00
C
Flavour: Butter
50
F2532/D
Flavour: Chocolate
50
NJ0159D1
Cocoa powder 100
Flavour: Vanilla
10
F544/D
Sweetener HA201 1 1 .4
Xanthan gum 15
Table 10
The third dosage unit may be in an oral dosage form such as a tablet or capsule containing approximately 100mg biotin, approximately 20mg coenzyme Q10, approximately 800mcg folic acid, approximately 10mg pantothenate, approximately 333 IU vitamin A in the form of beta carotene, approximately 24mcg vitamin B1 in the form of
methylcobalamin;approximately 4mg vitamin B2, approximately 18mg vitamin B3 in the form of nicotenamid, 10mg of vitamin B2 and approximately 500 IU vitamin D3.
The typical formulation of the third dosage unit is illustrated in table 1 1 .
Table 1 1
The concentration of vitamin D3 will typically be 500 IU per day, however if a genetic variation is discovered in a patient that blocks the activation of vitamin D3, vitamin D2 may be added to the regimen. The concentration of vitamin D2 will typically be 50 000 IU per day until blood levels normalise to 50ng - 100ng. The concentration of vitamin D2 advised may then be reduced to 50 000 IU 3 times per week.
The fourth dosage unit may be in the form of a capsule or tablet containing approximately 120mg alpha lipoic acid, approximately 4mg of 5% extract of astaxanthin, approximately 30mg of grape seed extract, approximately 30mg of resveratrol, approximately 100mg of rooibos teas exteract, approximately 50 mg roship vitamin C, approximately 10mg 0.3% sulforaphane, approximately 1665 IU vitamin A in the form of beta carotene, approximately 15 IU alpha tocopherol and approximately 100 meg elemental L-
selenomethionine.
The fourth dosage unit is illustrated in table 12 below.
Table 12
The fifth dosage unit may be a capsule or tablet containing approximately 3mg boron, approximately 100mg calcium, approximately 120 meg chromium in the form of niccotinoglycinate amino acid chelate, approximately 2mg copper, approximately 100mg magnesium as glycinate amino acid chelate or magnesium oxide, approximately 75 meg molybdenum, approximately 100mg potassium in the form of potassium glycinate amino acid complex or potassium gluconate or asparate or citrate or iodide, approximately 15mg zinc in the form of ACC, approximately 100mg salmon oil and approximately 500mg evening primrose oil. The fifth dosage unit is illustrated in table 13 below.
Minerals and Trace elements (Capsule
or Tablet) Values Units Lowest Highest
Boron 3 mg 2.25 3.75
Calcium 100 mg 75.00 125
Chromium 120 meg 90.00 150
Copper 2 mg 1 .50 2.5
Magnesium 100 mg 75.00 125
nc mg . .
Table 13
The sixth dosage unit typically contains 1000mg salmon oil and 500mg evening primrose oil as illustrated in table 14.
Docosahexaenoic (DHA) Units Lowest Highest
Eicosapentaenoic Acid(EPA)
Salmon Oil (Fish Oil) evening 1000 mg 750.00 1250
Container in the box
Evening Primrose Oil evening 500 mg 375.00 625
Table 14
In the case where patients are diagnosed with a mental condition such as depression, additional Salmon Oil may be taken in the morning, the concentration whereof may vary between 500 - 1000 mg. This will be supplied as additional capsules.
A seventh dosage unit consisting of capsules containing Lecithin, may be added if it is not included in the protein shake, or in addition to that which is contained in the protein shake:
The Lecithin may also be supplied as granules to be sprinkled over breakfast cereal.
Claims
1 . A kit for use in a method of inhibiting damage or demise of myelin- producing cells, which method comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements, the kit having a container with a plurality of distinct compartments, each compartment containing a plurality of dosage units of the nutritional supplements, the nutritional supplements constituting sufficient daily multi-unit doses for a period of time.
2. A kit as claimed in claim 1 , in which the nutritional supplements are selected from iron, essential amino acids, lipids, minerals and vitamins.
3. A kit as claimed in either claim 1 or claim 2, in which the kit includes amino acids selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine.
4. A kit as claimed in claim 3, in which the kit includes one or more of the following amino acids in the following amounts:
1235mg leucine;
890mg isoleucine;
995mg lysine;
175mg tryptophane;
315mg methionine;
610mg phenylalanine;
570mg threonine;
840mg valine; and
340mg histidine.
5. A kit as claimed in any one of the preceding claims, in which the kit includes lipids selected from evening primrose oil, salmon oil and lecithin.
6. A kit as claimed in claim 5, in which the kit includes one or more of the following lipids in the following amounts:
approximately 500mg evening primrose oil;
approximately 500mg salmon oil; and
approximately 300mg lecithin.
7. A kit as claimed in any one of the preceding claims, in which the kit includes vitamins selected from beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3.
8. A kit as claimed in claim 7, in which the kit includes one or more of the following vitamins in the following amounts:
3mg beta carotene;
350mg vitamin C;
40mg vitamin E;
3mg vitamin B1 ;
4mg vitamin B2;
20mg nicotinaminde;
24μg vitamin B12;
10mg vitamin B6;
10mg panthothenate;
50 000 IU vitamin D2; and
500 IU vitamin D3.
9. A kit as claimed in any one of the preceding claims, in which the kit includes minerals selected from calcium, magnesium, copper, zinc, manganese, chromium, molybdenum and selenium.
10. A kit as claimed in claim 9, in which the kit includes one or more of the following minerals in the following amounts:
28.5mg calcium;
150mg magnesium;
1 mg copper;
15mg zinc;
2.5mg manganese;
10C^g chromium;
100μg molybdenum; and
6C^g selenium.
1 1 . A kit as claimed in any one of the preceding claims, in which the kit includes 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100μg chromium, 100μg molybdenum and 60μg selenium and optionally 15mg iron.
12. A kit as claimed in any one of the preceding claims, in which the nutritional supplements are oral dosage forms selected from tablets, capsules, fluids, powders and dietary shakes.
13. A kit as claimed in claim 12, in which one or more of the dosage forms include two or more of the nutritional supplements.
14. A kit as claimed in any one of the preceding claims, in which the kit contains multiple dosage units of the same nutritional supplement.
15. A kit as claimed in any one of claims 1 to 13, in which the kit has at least 28 compartments containing a daily dosage unit of each of the different nutritional supplements.
16. A kit as claimed in any one of the preceding claims, in which each of the compartments has a separate cap.
17. A kit as claimed in claim 16, in which the kit has at least one lid covering the compartments and corresponding caps.
18. A nutritional composition for use in a method of inhibiting damage or demise of myelin-producing cells, which method comprises administering to a patient in need of such treatment an effective amount of a plurality of nutritional supplements; the supplements being selected from iron, essential amino acids, lipids, minerals and vitamins.
19. A nutritional composition as claimed in claim 18, in which the amino acids are selected from leucine, isoleucine, lysine, tryptophan, methionine, phenylalanine, threonine, valine and histidine.
20. A nutritional composition as claimed in either one of claims 18 or 19, in which the nutritional composition includes one or more amino acids in the following amounts:
1235mg leucine;
890mg isoleucine;
995mg lysine;
175mg tryptophane;
315mg methionine;
610mg phenylalanine;
570mg threonine;
840mg valine; and
340mg histidine.
21 . A nutritional composition as claimed any one of claims 18 to 20, in which the lipids are selected from evening primrose oil, salmon oil and lecithin.
22. A nutritional composition as claimed in any one of claims 18 to 21 , in which the nutritional composition includes one or more lipids in the following amounts:
about 500mg evening primrose oil;
about 500mg salmon oil;
about 300mg lecithin.
23. A nutritional composition as claimed in any one of claims 18 to 22, in which the vitamins are selected from beta carotene, vitamin C, vitamin E, vitamin B1 , vitamin B2, nicotinamide, folic acid, vitamin B12, vitamin B6, pantothenate, vitamin D2 and vitamin D3.
24. A nutritional composition as claimed in any one claims 18 to 23, in which the nutritional composition includes one or more vitamins in the following amounts:
3mg beta carotene;
350mg vitamin C;
40mg vitamin E;
3mg vitamin B1 ;
4mg vitamin B2;
20mg nicotinamide;
24μg vitamin B12;
10mg vitamin B6;
10mg panthothenate;
50 000 IU vitamin D2; and
500 IU vitamin D3;
25. A nutritional composition as claimed in any one of claims 18 to 24, in which the minerals are selected from calcium, magnesium, copper, zinc, manganese, chromium, molybdenum and selenium.
26. A nutritional composition as claimed in any one of claims 18 to 25, in which the nutritional composition includes one or more minerals in the following amounts:
28.5mg calcium;
150mg magnesium;
1 mg copper;
15mg zinc;
2.5mg manganese;
100μg chromium;
100μ9 molybdenum; and
60μ9 selenium.
27. A nutritional composition as claimed in any one claims 18 to 26, in which the nutritional composition comprises 1235mg leucine, 890mg isoleucine, 995mg lysine, 175mg tryptophan, 3154mg methionine, 610mg phenylalanine, 570mg threonine, 840mg valine, 340mg histidine, 3mg beta carotene, 350mg vitamin C, 40mg vitamin E, 3mg vitamin B1 , 4mg vitamin B2, 20mg nicotinamide, 5mg folic acid, 24 μg vitamin B12, 10mg vitamin B6, 10mg pantothenate, 50 000 IU mg vitamin D2, 500 IU vitamin D3, 28.5mg calcium, 150mg magnesium, 1 mg copper, 15mg zinc, 2,5mg manganese, 100μg chromium, 100μg molybdenum and 60μg selenium and optionally 15mg iron.
28. A nutritional composition as claimed in any one of the claims 18 to 27, in which the nutritional supplements are contained in a plurality of dosage units.
29. A nutritional composition as claimed in claim 28, in which the dosage units are oral dosage forms selected from tablets, capsules, fluids, powders and dietary shakes.
30. A nutritional composition as claimed in either claim 28 or claim 29, in which one or more of the dosage units contains two or more of the nutritional supplements.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA2015/02635A ZA201502635B (en) | 2012-09-28 | 2015-04-20 | Nutritional kit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA201207347 | 2012-09-28 | ||
ZA2012/07347 | 2012-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014049566A2 true WO2014049566A2 (en) | 2014-04-03 |
WO2014049566A3 WO2014049566A3 (en) | 2014-09-12 |
Family
ID=49765593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/058945 WO2014049566A2 (en) | 2012-09-28 | 2013-09-27 | Nutritional kit |
Country Status (2)
Country | Link |
---|---|
WO (1) | WO2014049566A2 (en) |
ZA (1) | ZA201502635B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800005508A1 (en) * | 2018-05-18 | 2019-11-18 | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. | |
IT201900025069A1 (en) * | 2019-12-20 | 2021-06-20 | Alidans S R L | ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES |
US12042477B2 (en) | 2016-02-23 | 2024-07-23 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050136106A1 (en) * | 2000-11-20 | 2005-06-23 | Adrian Sandler | Therapeutic placebo enhancement of commonly used medications |
US7899527B2 (en) * | 2004-05-13 | 2011-03-01 | Palo Alto Investors | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase |
CA2671806A1 (en) * | 2006-12-08 | 2008-06-19 | Austin M. Derfus | Remotely triggered release from heatable surfaces |
US20090053176A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
HUP0800414A2 (en) * | 2008-07-04 | 2010-10-28 | Pecsi Tudomanyegyetem | Pharmaceutical combination |
CA2757287C (en) * | 2009-03-31 | 2019-09-10 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
US20120245552A1 (en) * | 2011-03-23 | 2012-09-27 | Pop Test Cortisol Llc | Combination Therapy |
-
2013
- 2013-09-27 WO PCT/IB2013/058945 patent/WO2014049566A2/en active Application Filing
-
2015
- 2015-04-20 ZA ZA2015/02635A patent/ZA201502635B/en unknown
Non-Patent Citations (1)
Title |
---|
None |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12042477B2 (en) | 2016-02-23 | 2024-07-23 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
IT201800005508A1 (en) * | 2018-05-18 | 2019-11-18 | Kit for use as a food supplement in the treatment of vitamin and / or mineral deficiencies in pediatrics. | |
IT201900025069A1 (en) * | 2019-12-20 | 2021-06-20 | Alidans S R L | ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES |
Also Published As
Publication number | Publication date |
---|---|
WO2014049566A3 (en) | 2014-09-12 |
ZA201502635B (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018304380B2 (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | |
US10517322B1 (en) | Dietary supplement formulations for promoting sleep | |
CA2703693C (en) | Anti-fatigue agent comprising amino acid composition | |
US20030166614A1 (en) | Method for reducing cholesterol and triglycerides | |
US20070004639A1 (en) | Methods and compositions for treating Parkinson's disease | |
ES2546055T3 (en) | Nutritional supplements for individuals 50 years or older to improve vitality, immunity, eye and bone health | |
US20050249823A1 (en) | Methods for the prevention or amelioration of neuropsychiatric and related diseases | |
US20220378731A1 (en) | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column | |
JP2023011800A (en) | ω3 FATTY ACIDS AND CHOLINE AS NEUROPROTECTANT IN PATIENTS WITH NO DEMENTIA | |
WO2014049566A2 (en) | Nutritional kit | |
JP5378406B2 (en) | Composition for the treatment of aseptic inflammation | |
US20210052533A1 (en) | Compositions comprising a metal and l-serine, and uses thereof | |
WO2013071278A1 (en) | Fatty acids and metal ions compositions and uses thereof | |
CA3111618A1 (en) | Magnesium-containing formulation and uses thereof | |
ES2965339T3 (en) | Method to support memory function and/or cognitive function | |
Božić et al. | Vitamin B1, eye and brain | |
BE1025418B1 (en) | Nutritional supplement and applications | |
Kelly et al. | A diagnostically reasoned case study with particular emphasis on B6 and zinc imbalance directed by clinical history and nutrition physical examination findings | |
Naples Federico | Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria | |
JPH04112823A (en) | Remedy for dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13805547 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13805547 Country of ref document: EP Kind code of ref document: A2 |